A review found growing evidence supporting cannabinoid use for CDKL5 Deficiency Disorder (CDD), drawing on proven CBD efficacy in similar syndromes (Dravet, Lennox-Gastaut), anecdotal reports, and an open-label trial showing seizure reduction in CDD specifically.
Families affected by CDD, pediatric neurologists, and rare disease researchers.
First comprehensive CDD-cannabis review
What the researchers found
Evidence supports cannabinoids for refractory epilepsies similar to CDD (Dravet, Lennox-Gastaut syndromes). Specific evidence for CDD includes multiple anecdotal reports and an open-label trial showing CBD was associated with significant seizure reduction. This provides the first comprehensive overview of cannabis potential for CDD.
Why it matters
CDD is an extremely debilitating genetic disorder with early-onset seizures that rarely respond to existing treatments. Parents are already seeking cannabis products, and this review provides the first organized assessment of the evidence specifically for this condition.
The numbers in context
CBD proven effective in Dravet and Lennox-Gastaut (Phase III RCTs). CDD-specific: multiple anecdotal reports plus open-label trial showing significant seizure reduction with CBD.
How the study worked
Comprehensive review covering cannabis history, mechanism of action, efficacy and safety in epilepsy, and specific evidence for CDKL5 Deficiency Disorder. Includes burden of disease analysis.
What this study cannot tell us
CDD-specific evidence is limited to anecdotal reports and one open-label trial. The syndrome is too rare for large RCTs. Extrapolation from Dravet and Lennox-Gastaut may not be fully valid. Mechanism of CBD action in CDD is unknown.
How to read the evidence
Rated preliminary because CDD-specific evidence is limited to anecdotal reports and one open-label trial.
When this study was published
Published in 2019. Additional CDD-cannabis research may have emerged since.
The bigger picture
CDKL5 Deficiency Disorder represents the frontier of cannabinoid epilepsy research: conditions too rare for large RCTs but devastating enough that families are not willing to wait for perfect evidence.
Questions still open
- Will controlled trials be feasible in this rare population? What CBD dose is optimal for CDD? Could genetic characteristics of CDD predict cannabinoid response?
Common questions
Can CBD help CDKL5 Deficiency Disorder seizures?
What is CDKL5 Deficiency Disorder?
Read the original research
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
Epilepsy research, 151, 31-39
Citation
Dale, Tristan; Downs, Jenny; Olson, Heather; Bergin, Ann Marie; Smith, Stephanie; Leonard, Helen. (2019). Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.. Epilepsy research, 151, 31-39. https://doi.org/10.1016/j.eplepsyres.2019.02.001
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk